As of 2026-10-07, the Intrinsic Value of Arrowhead Pharmaceuticals Inc (ARWR) is 735.67 USD. This ARWR valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 61.54 USD, the upside of Arrowhead Pharmaceuticals Inc is 1,095.40%.
The range of the Intrinsic Value is 550.52 - 847.37 USD
Based on its market price of 61.54 USD and our intrinsic valuation, Arrowhead Pharmaceuticals Inc (ARWR) is undervalued by 1,095.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (8,880.57) - (1,084.34) | (1,877.26) | -3150.5% |
| DCF (Growth 10y) | (1,248.85) - (9,520.31) | (2,095.36) | -3504.9% |
| DCF (EBITDA 5y) | 550.52 - 847.37 | 735.67 | 1095.4% |
| DCF (EBITDA 10y) | 1,183.29 - 2,054.91 | 1,679.29 | 2628.8% |
| Fair Value | -11.36 - -11.36 | -11.36 | -118.45% |
| P/E | (44.47) - 12.05 | (19.89) | -132.3% |
| EV/EBITDA | (24.37) - 227.38 | 90.31 | 46.7% |
| EPV | (33.93) - (44.76) | (39.35) | -163.9% |
| DDM - Stable | (31.27) - (347.04) | (189.15) | -407.4% |
| DDM - Multi | 14.97 - 129.85 | 26.90 | -56.3% |
| Market Cap (mil) | 8,668.52 |
| Beta | 1.74 |
| Outstanding shares (mil) | 140.86 |
| Enterprise Value (mil) | 9,874.45 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.84% |
| Cost of Debt | 5.00% |
| WACC | 6.74% |